Current and emerging biologics for the treatment of hemophilia

References

• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801–1809.
   PubMed Web of Science ®Google Scholar
• Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. SeminThrombHemost. 2013;39:702–710.
   Google Scholar
• White GC II, Rosendaal F, Aledort LM, et al. Factor VIII and factor IX subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and Factor IX of the scientific and standardization committee of the international society on thrombosis and haemostasis. ThrombHaemost. 2001;85(3):560.
   Google Scholar
• Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379:1447–1456.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauer-Bunschoten EP, et al. Treatment guidelines working group on behalf of the world federation of hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e 1–47.
   Web of Science ®Google Scholar
• Fisher K, Astermark J, Van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate dose regimen to a high dose regimen. Haemophilia. 2002;8:753–760.
   PubMed Web of Science ®Google Scholar
• Laffan M. New products for treatment of haemophilia. Br J Haematol. 2016;172:23–31.
   PubMed Web of Science ®Google Scholar
• Collins PW. Personalized prophylaxis in haemophilia patients. Haemophilia. 2012;18(Suppl 4):131–135.
   PubMed Web of Science ®Google Scholar
• Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99–105.
   PubMed Web of Science ®Google Scholar
• Castaman G, Linari S. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Rev Hematol. 2018;11(7):567–576.
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13:606–612.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS study group. Blood. 2003;102:2358–236346.
   PubMed Web of Science ®Google Scholar
• Dolan G, Benson G, Duffy A, et al. Haemophilia B: where are we now and what does the future hold? Blood Rev. 2018;32(1):52–60.
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. European haemophilia therapy standardisation board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16:747–766.
   PubMed Web of Science ®Google Scholar
• Young G, Shafer FE, Rojas P, et al. Single 270 micro kg(−1)-dose rFVIIa vs. Standard 90 micro kg(−1)-dose rFVIIa and aPCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287–294.
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. FENOC study group. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA novoseven comparative (FENOC) study. Blood. 2007;109:546–551.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients – from a clinical and farmacoeconomic perspective. Haemophilia. 2014;20(Suppl. 6):17–26.
   PubMedGoogle Scholar
• Di Michele DM. Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost. 2011;9:216–225.
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365:1684–1692.
   PubMed Web of Science ®Google Scholar
• Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20:65–72.
   PubMed Web of Science ®Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913.
   PubMed Web of Science ®Google Scholar
• Ljung R. Aspects of prophylactic treatment of hemophilia. Thromb J. 2016;14(Suppl 1):60–63.
   Google Scholar
• Gale AJ. Current understanding of hemostasis. Toxicol Pathol. 2011;39(1):273–280.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000;105:783–791.
   PubMed Web of Science ®Google Scholar
• Morrissey JH, Macik BG, Neuenschwander PG, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734–744.
   PubMed Web of Science ®Google Scholar
• Butenas S, Van’t Veer C, Mann KG. “Normal” thrombin generation. Blood. 1999;94:2169–2178.
   PubMed Web of Science ®Google Scholar
• Dalback B. Blood coagulation. Lancet. 2000;355:1627–1632.
   PubMed Web of Science ®Google Scholar
• Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690–694.
   PubMed Web of Science ®Google Scholar
• Lane DA, Philippou H, Hungtington JA. Directing thrombin. Blood. 2005;106:2605–2612.
   PubMed Web of Science ®Google Scholar
• Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA. 1981;78:2249–2252.
   PubMed Web of Science ®Google Scholar
• Franchini M, Montagnana M, Targher G, et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost. 2009;35:307–312.
   PubMed Web of Science ®Google Scholar
• Negrier C, Berruyer M, Durin A, et al. Increased thrombin generation in a child with a combined factor IX and protein C deficiency. Blood. 1993;81:690–695.
   PubMed Web of Science ®Google Scholar
• Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol. 2007;138:541–544.
   PubMed Web of Science ®Google Scholar
• Bollinger D, Szlam F, Suzuki N, et al. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thromb Haemost. 2010;103:1233–1238.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–1574.
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–2053.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117:1348–1357.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130:2463–2468.
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12:206–213.
   Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. The anti-factor IXa/X bispecific antibody ACE910 prevents spontaneous joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124:3165–3171.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in health subjects. Blood. 2016;127:1633–1641.
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891–1899.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia with inhibitors. N Engl J Med. 2017;377:809–818.
   PubMed Web of Science ®Google Scholar
• Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety, and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia a with inhibitors [abstract]. Blood. 2017;130:85.
   Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–822.
   PubMed Web of Science ®Google Scholar
• Pipe S, Jiménez-Yuste V, Shapiro A, et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors – results from the phase 3 HAVEN 4 study. Haemophilia. 2018;24(S5),abs.861,212-213.
   Google Scholar
• Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132:633.
   Web of Science ®Google Scholar
• Young G, Liesner R, Sidonio RF, et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood. 2018;132:632.
   Web of Science ®Google Scholar
• Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two multicenter, open label phase 3 studies of emicizumab in person with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood. 2017;130:89.
   Web of Science ®Google Scholar
• Santagostino E, Mancuso ME, Novembrino C, et al. Management of joint replacementin hemophilia A with inhibitors during emicizumab prophylaxis. Blood. 2017;130:2360.
   PubMed Web of Science ®Google Scholar
• Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in hemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018;24:344–347.
   PubMed Web of Science ®Google Scholar
• Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016;36:9–14.
   PubMed Web of Science ®Google Scholar
• Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 1995;6:388–394.
   PubMed Web of Science ®Google Scholar
• Prasad S, Lillicrap D, Labelle A, et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008;111:672–679.
   PubMed Web of Science ®Google Scholar
• Petersen LC. Hemostatic properties of a TFPI antibody. Thromb Res. 2012;129(Suppl2):44–45.
   Google Scholar
• Waters EK, Sigh J, Friederich U, et al. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23:769–776.
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119:5871–5878.
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friederich U, et al. Safety and pharmacokinetics of anti-TFPIantibody (concizumab) in healthy volunteers and patients with hemophilia A: a randomized first human dose trial. J Thromb Haemost. 2015;13:743–754.
   PubMed Web of Science ®Google Scholar
• Eichler H, Angchaisuksiri P, Kavakli K, et al.Safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A: a phase 1b, randomized trial. J Thromb Haemost. 2018 Aug 23. DOI: 10.1111/jth.14272
   PubMed Web of Science ®Google Scholar
• Gu JM, Zhao XY, Schwarz T, et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. Aaps J. 2017;1186–1195.
   PubMed Web of Science ®Google Scholar
• Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human (FIH) study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-06741086, an anti-TFPI monoclonal antibody, following administration of single subcutaneous or intravenous doses in healthy adult male volunteers.Berlin, Germany: ISTH Congress; 2017 8–13 Jul.
   Google Scholar
• Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med. 2015;373:389–391.
   PubMed Web of Science ®Google Scholar
• Schgal A, Barros S, Ivanciu L, et al. A RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21:492–497.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAitherapy. N Engl J Med. 2017;377:819–828.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Georgiev P, Mant T, et al. Fitusiran, an investigational RNAi therapeutic targeting antithrombin for treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitors [Abstract]. Res Pract Thromb Haemost. 2017;1(S2): abs PB 212, 346.
   Google Scholar
• Tiede A. Thromboembolic risks of non-factor replacement therapies in hemophilia. Hamostaseologie. 2017;37:307–310.
   PubMed Web of Science ®Google Scholar
• Alnylam press release of 9th November 2017. cited 2017 Nov 30 Available at: http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-successful-oucome-following-fda-type-meeting.
   Google Scholar
• Polderdijk SG, Adams TE, Ivanciu L, et al. Baglin TP Huntington JA. Design and characterization of an APC-specific serpin for treatment of hemophilia. Blood. 2017;129(1):105–113.
   PubMed Web of Science ®Google Scholar
• Polderdijk SGI, Baglin TP, Huntington JA. Targeting activated protein C to treat hemophilia. Curr Opin Hematol. 2017;24(5):446–452.
   PubMed Web of Science ®Google Scholar
• Prince R, Bologna L, Manetti M, et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood. 2018;131:1360–1371.
   PubMed Web of Science ®Google Scholar